In the volatile stock market, significant price drops usually alarm investors, but according to Goldman, Hapvida remains an exception. Goldman Sachs views the 18% drop in Hapvida, a top Brazilian healthcare provider, since May 20 as an ideal buying chance. This advice follows the company’s strategic merger with NotreDame, marking a pivotal moment promising operational […]
